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Abstract
Water-soluble corroles with inherent fluorescence can form stable self-assemblies with tumor-
targeted cell penetration proteins, and have been explored as agents for optical imaging and 
photosensitization of tumors in preclinical studies. However, the limited tissue-depth of excitation 
wavelengths limits their clinical applicability. To examine their utility in more clinically-relevant 
imaging and therapeutic modalities, here we have explored the use of corroles as contrast 
enhancing agents for magnetic resonance imaging (MRI), and evaluated their potential for tumor-
selective delivery when encapsulated by a tumor-targeted polypeptide. We have found that a 
manganese-metallated corrole exhibits significant T1 relaxation shortening and MRI contrast 
enhancement that is blocked by particle formation in solution but yields considerable MRI contrast 
after tissue uptake. Cell entry but not low pH enables this. Additionally, the corrole elicited tumor-
toxicity through the loss of mitochondrial membrane potential and cytoskeletal breakdown when 
delivered by the targeted polypeptide. The protein-corrole particle (which we call HerMn) 
exhibited improved therapeutic efficacy compared to current targeted therapies used in the clinic. 
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Taken together with its tumor-preferential biodistribution, our findings indicate that HerMn can 
facilitate tumor-targeted toxicity after systemic delivery and tumor-selective MR imaging 
activatable by internalization.
Graphical abstract
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INTRODUCTION
Multifunctional therapeutics, or “theranostics”, combine several activities such as imaging, 
diagnostic, or therapeutic functions into a single complexed particle, thus providing a 
powerful approach to simultaneously detecting, diagnosing, and treating disease. (1, 2) 
Engineering a theranostic commonly entails chemically conjugating different agents to a 
scaffold, such as a polymer, with each agent imparting a different function (i.e. tissue or cell 
targeting, membrane penetration, drug delivery, imaging). A potential complication with 
such approaches is the requirement for multiple covalent coupling reactions that increase the 
complexity and heterogeneity of the complex, and may abrogate the activities of its separate 
components.
Sulfonated corroles can overcome this complication because they can non-covalently 
assemble with protein-based delivery agents while bearing potential theranostic functions, 
thus forming a multifunctional particle from only two components. Sulfonated corroles are 
macrocyclic molecules with structural similarity to porphyrins and bear several notable 
characteristics that lend to their use as multifunctional payloads. The amphiphilicity of 
sulfonated corroles contributes to their water-solubility and tight non-covalent binding to 
proteins, (3–5) thus enabling rapid assembly with carrier proteins and delivery in 
physiological conditions. The net negative charge of sulfonated corroles prevents their 
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penetration into cells in the absence of a membrane-lytic molecule, (3) thus enabling 
selective cell entry directed by the delivery agent. The incorporation of a metal ligand in the 
corrole ring can contribute to imaging and therapeutic potential. For example, non-
metallated and gallium(III)-metallated corroles are both cytotoxic and intensely fluorescent, 
(3–5) whereas iron(III) and manganese(III)-metallated corroles are nonfluorescent and have 
exhibited robust antioxidant activity on neuronal tissue.(6)
Whereas fluorescent corroles have been examined as agents for optical imaging of tumors in 
mice (7) and photosensitization of tumor cells in vitro, (8, 9) the limited tissue-depth of 
excitation wavelengths limits their clinical applicability. To assess the feasibility of using 
more clinically-relevant imaging modalities, here we explored the utility of corroles as 
contrast enhancing agents for magnetic resonance imaging (MRI), thus expanding the 
theranostics benefits inherent to the corroles.
In the current study, a comparison of in vitro T1 relaxation shortening and MRI contrast 
enhancement activities between sulfonated gallium(III), iron(III), and manganese(III)-
metallated corroles singled out the manganese (Mn) compound as a candidate for further 
evaluation in the context of a tumor-targeted particle. Assembly of the particle, HerMn, 
resulted from binding of the Mn-corrole (or S2Mn) with the recombinant protein, 
HerPBK10. The peptide domains comprising HerPBK10 impart functions that can facilitate 
the targeted delivery (through binding to the human epidermal growth factor receptor or 
HER) and cell entry of membrane-impermeant molecules (10–13). Importantly, HER2–3 
heterodimers, which are recognized by the heregulin-derived targeting ligand of HerPBK10, 
are predominantly displayed on HER2+ tumors (14), hence targeting is preferential to 
HER2+ tumor cells (11, 13, 15). In agreement, we have shown elsewhere that HerPBK10 
can mediate preferential targeting in vivo to tumors expressing relatively higher HER2–3 
levels in comparison to tumors expressing low/negligible levels of these receptor subunits 
(15).
Here we present evidence that the sulfonated Mn(III) corrole can elicit MRI contrast 
enhancement as well as tumor-selective toxicity when delivered by HerPBK10. The tumor-
toxic activity comes somewhat as a surprise given the cytoprotective effects that this corrole 
has exhibited previously on non-tumor, specifically neuronal, tissue.(6) Hence, in this study, 
we also probe the mechanism of tumor-cell toxicity elicited by the Mn-corrole, and compare 
therapeutic efficacy in vitro against current targeted and non-targeted therapies used in the 
clinic. Finally, interrogating the MRI capability of protein-bound vs. free corrole yielded 
findings suggesting that contrast enhancement in tissue is activated by pH-independent 
mechanisms relying on cell uptake.
MATERIALS AND METHODS
Materials
The recombinant fusion protein, HerPBK10 (comprised of the receptor-binding domain of 
heregulin-α fused to the adenovirus penton base modified by a carboxy-terminal decalysine 
tail) (16), was produced and isolated from a bacterial expression system as described 
previously.(13) S2Mn (chemical structure shown in Fig. 1A) was synthesized, reconstituted 
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in phosphate-buffered saline (PBS), and quantified as described previously.(3) HerMn 
complexes were assembled non-covalently by combining HerPBK10 and S2Mn as 
described.(10) Briefly, S2Mn and HerPBK10 were mixed at a corrole:protein ratio of 30:1 
(the maximum number of corrole molecules bound per HerPBK10 protein, as determined 
previously)(3, 11) in PBS and agitated gently on ice for 1h, followed by ultrafiltration (50K 
mwco) until the volume was reduced from 12 to <0.5 mL, to remove any free 
unincorporated corrole and concentrate the particle mixture. Retentates (containing HerMn 
particles) were recovered and analyzed by absorbance spectroscopy to determine the corrole 
and protein concentrations in HerMn and resulting corrole:protein ratio in each HerMn 
preparation, which remained at approx. 30:1 molar ratio after filtration (Table S1). The 
concentration used for cell treatment was based on the corrole concentration in each 
complex.
Particle sizing
A Malvern ZEN 3600 Zetasizer Nano was used for Dynamic Light Scattering (DLS) 
measurement. Samples were pipetted into a low volume quartz cuvette with appropriate 
concentrations to prevent aggregation. Data shown represent the particle size distribution 
(PSD), which reports the most frequent particle size in the sample accounting for intensity 
fluctuations of larger particles. The PSD of each sample was acquired at ≥9 measurements/
sample, with each measurement comprising 20 runs averaging 34,000 particle-counts/sec. 
Intensity of particles was computed via Zetasizer Software version 7.01, which applies the 
Stokes-Einstein equation to correlate the change in the scattering intensity and particle 
movements.
Electron microscopy
Transmission electron microscopy (TEM) was performed using a TF20 (FEI Tecnai) 
transmitting electron microscope fitted with a field emission gun, operated at 200 kV. 
HerMn samples were prepared by dispersing the nanoparticles in hexane and dropping the 
solution onto an amorphous carbon coated grid. Images were obtained using a TIETZ 
F415MP CCD camera and processed using TIETZ Tomography package or ImageJ 
software.
Cells
MDA-MB-435 (HER2+ human ductal carcinoma) cell lines were obtained from the National 
Cancer Institute, and MDA-MB-231 (HER2− human mammary adenocarcinoma) and 
SKBR3 (HER2+ human mammary adenocarcinoma) cell lines were obtained from ATCC. 
BT-474 (HER2+ human ductal carcinoma) cells were a kind gift from Dr. Xiaojiang Cui 
(Cedars-Sinai Medical Center). Cell lines were maintained at 37°C in complete media 
[Dulbecco’s modified Eagle’s medium (DMEM), 10% fetal bovine serum and 100 U/mL 
penicillin/100 µg/mL streptomycin] at 5% CO2. We previously verified the relative cell 
surface levels of HER2 on these cells by ELISA under non-permeabilizing conditions.(17)
Human cardiosphere-derived cells (CDCs) were prepared as described previously.(18) 
Briefly, endomyocardial biopsies from the right ventricular aspect of the interventricular 
septum were obtained from healthy hearts of deceased tissue donors. Heart biopsies were 
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minced into small fragments and briefly digested with collagenase. Explants were then 
cultured on 20 mg/ml fibronectin (BD biosciences)-coated dishes. Stromal-like flat cells and 
phase-bright round cells grew out spontaneously from the tissue fragments and reached 
confluence by 2–3 weeks. These cells were then harvested using 0.25% trypsin (GIBCO) 
and cultured in suspension on 20 mg/ml poly d-lysine (BD Biosciences) to form self-
aggregating cardiospheres. CDCs were obtained by seeding cardiospheres onto fibronectin-
coated dishes and passaged. CDC cultures were maintained at 5% CO2 at 37°C, using 
IMDM basic medium (GIBCO) supplemented with 20% FBS (Hyclone), 1% penicillin/
streptomycin, and 0.1 ml 2-mercaptoethanol. Human heart biopsy specimens, from which 
CDCs were grown, were obtained under a protocol approved by the institutional review 
board for human-subject research.
Cell Toxicity Assays
Indicated cells were plated at 10,000 cells/well in a 96-well dish. 48h later, media was 
replaced with fresh complete media containing the indicated concentrations of HerMn, 
S2Mn, HerPBK10 or saline in 100 µL final volume/well. Plates were rocked for 4h at 37°C 
followed by further incubation without rocking for 20h at 37°C. Cell number was then 
determined by crystal violet (CV) assay as described previously.(10) Human CDCs were 
plated at 8,000 cells per well in a 96-well dish. 48h later, media was replaced with fresh 
complete media containing the indicated concentrations of HerPBK10, S2Mn, HerMn or 
doxorubicin, in 40 µL total volume/well. Plates were rocked for 4h at 37°C followed by 
supplementation with complete media to a 0.1 mL final total vol and continued incubation 
without rocking for 32h at 37°C. Cell survival was determined by MTS assay (Promega).
Mitochondrial Membrane Permeability Assay
MDA-MB-435 cells were plated in Delta T chambers at 100,000 cells/chamber and 
incubated for 48h. Media was replaced by 1 mL of fresh complete media containing the 
indicated concentrations of HerMn, S2Mn, HerPBK10 or PBS, followed by incubation for 
24h at 37°C. Cells were then washed with Hank’s Buffered Salt Solution (HBSS), and 
incubated in 30 nM tetramethylrhodamine methyl ester (TMRM; Invitrogen) in HBSS, 1h at 
37°C. Images were acquired at different z-depths using laser scanning confocal microscopy. 
Mitochondrial membrane potential was quantified from a z-stacked maximum intensity 
projection of each acquired image by calculating the average fluorescence intensity for all 
cells in each field of view, from 3 independent experiments. TMRM has an excitation peak 
of 532 nm and an emission peak of 580 nm, so fluorescence was measured in the 550–620 
nm range. The distribution of TMRM, a cationic dye, across the mitochondrial membrane is 
governed primarily by the Nernst equation,(19) whereas transmembrane potential collapse 
results in its diffusion into the cytosol, thus reducing its intracellular fluorescence intensity.
(20)
Immunofluorescence
MDA-MB-435 cells were plated on coverslips in a 6-well dish at 100,000 cells/well and 
incubated for 48h before media was replaced with 1 mL fresh media containing indicated 
concentrations of HerMn, S2Mn, HerPBK10 or PBS. Cells were incubated a further 24h 
followed by fixation and processing for immunofluorescence as described previously.(10) 
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Where indicated, cells were pre-incubated with 5 mM Tiron for 1h before receiving HerMn. 
Specimens received anti- alpha-tubulin primary and Alexafluor 488 goat anti-mouse 
secondary antibodies (Invitrogen) at 1:100 and 1:1000 dilution in 1% BSA/PBS, 
respectively. Texas Red-X Phalloidin (Invitrogen) at 1:100 dilution was co-incubated with 
the secondary antibody, followed by incubation with 300 nM DAPI for 5 minutes before 
washing and mounting. Images were acquired using a Leica SPE laser scanning confocal 
microscope.
Animals
Nude (NU/NU) mice were obtained from Charles River Laboratories, Inc. All procedures 
involving mice were performed following Institutional of Animal Care and Use Committee 
(IACUC)-approved protocols in accordance with the institutional and national guide for the 
care and use of laboratory animals.
Tumor Growth and Monitoring In vivo
Female nude mice (NU/NU, 6 weeks; Charles River) received subcutaneous bilateral flank 
implants of 1×107 MDA-MB-435 human HER2+ cancer cells per implant. When average 
tumor sizes reached ~200 mm3, mice were randomized and classified into 4 groups, each 
receiving daily injections for 6 sequential days of: HerMn or S2Mn at 5 nmoles corrole per 
injection; HerPBK10 at equivalent protein concentration to that of HerMn; or saline, which 
served as a mock-treatment control. Tumor volumes (height × width × depth) were 
measured manually by caliper. Data were analyzed using a one-way ANOVA followed by a 
Bonferroni post hoc test.
Xenogen Imaging
HerPBK10 and BSA were separately labeled with Alexafluor-680 at primary amines and 
isolated from free, unconjugated dye by size exclusion chromatography using a commercial 
protein labeling kit, following manufacturer’s protocol (LifeTechnologies). The labeled 
HerPBK10 or BSA was then combined with S2Mn to form HerMn or BSA-Mn particles, 
and processed by ultrafiltration as described earlier, which further removed any free dye and 
corrole molecules. The UV/Vis spectra of retentates (containing particles) were obtained to 
calculate the concentration of corroles (see Table S1) and dye (184,000 cm−1M−1 extinction 
coefficient at 679 nm) in the HerMn or BSA-Mn sample. Protein concentration in the 
sample was determined by Bradford-based (Bio-Rad) protein assay. Mice bearing MDA-
MB-435 flank tumors implanted as described earlier received 12 nmol of Alexafluor 680-
labeled HerMn (total volume 125 µL), or BSA-Mn by tail vein injection, and immediately 
imaged at the indicated time points by a Xenogen Spectum imager using 640 nm excitation 
and 700 nm emission filters. After whole animal imaging, mice were sacrificed and tissues 
harvested for imaging using the same parameters, with images of all tissues from each 
mouse acquired simultaneously. Epifluorescence images were normalized to one another by 
adjusting the minimum fluorescence values to the same level before calculating average 
fluorescence intensities of the overall region of each selected tissue. Tissue fluorescence was 
graphed by normalizing the fluorescence of each tissue to the liver.
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Magnetic Resonance (MR) Studies
A 9.4 T Bruker BioSpec 94/20 was used to assess T1 relaxation and contrast enhancement 
for in vivo studies involving IT injections and all in vitro studies. For in vitro studies, change 
in relaxation time was captured and analyzed using a RARE sequence with varying 
repetition times. The relaxation times were determined by least square fitting of the signal 
from the region of interest representing the different concentrations.
To determine the effect of cellular uptake on S2Mn or HerMn -mediated T1 relaxation time 
shortening, MDA-MB-435 cells were first detached from cell culture flasks using 2 mM 
EDTA in PBS and washed three times using PBS supplemented with 0.01% of Ca2+ and 
Mg2+. 1×107 cells per sample were then incubated on ice for 30 min with 120 nM of S2Mn 
or HerMn (with respect to corrole concentration) to promote cell surface binding but not 
internalization. Cells were then warmed to 37°C for 1h to promote uptake, followed by 
washing three times with PBS to remove non-internalized S2Mn or HerMn. Cell pellets 
were suspended in 100 µL of PBS and subject to MRI as described earlier. Afterwards, cell 
lysates were prepared and assessed by absorbance spectroscopy to determine the 
concentration of internalized corrole.
For experiments involving intratumoral (IT) injections in vivo, nude mice with bilateral 
flank human HER2+ MDA-MB-435 tumors (size: ~95 mm3) received IT injections of S2Mn 
at increasing concentrations (30 µL of 0, 1, 10, 100, and 1000 µM solutions), with each 
higher dose injected sequentially into the same tumor. Equivalent volumes of saline were 
injected into the contralateral tumor. T1 changes and T1-mapped images of the tumor 
regions were acquired after each injection by MRI. A different mouse bearing similar 
tumors received HerMn following a similar regimen. Specifically, IT injections were 
comprised of 100 µL of 500 µM HerMn delivered once per day for eight days. MRI was 
conducted immediately after the eighth injection. MRI signals were quantified by acquiring 
each image at eight different recovery intervals, producing an exponential recovery curve 
that was fit with a standard equation, Mo=Minf(1−e-RT/T1) where Mo=observed 
magnetization, Minf=max polarization at infinite time, RT=delay time between the saturation 
and acquisition. Standard deviations were derived from least squared fitting of the data.
For experiments involving systemic delivery in vivo, nude mice bearing subcutaneous flank 
human HER2+ MDA-MB-435 tumors (size ~100 mm3) received daily tail vein injections 
(100 µL/injection) of HerMn or S2Mn (each at 8 nmol corrole/injection), or saline for 8 days 
or 0.1 mmol/kg gadolinium (Optimark™ gadoversetamide) for 10 minutes prior to imaging. 
Mice were subjected to MRI utilizing a 7T Bruker BioSpin 7 following the eighth injection. 
Imaging was performed using a T1-weighted spin-echo sequence, and 2D-acquisition with 
the following parameters: repetition time (TR)=1000 ms, echo time (TE)=9 ms, number of 
signal averages (NSA)=2, 3×3 cm field of view (FOV), forty-six 0.5 mm-thick slices and a 
334 µm in-plane resolution. Images were analyzed using online imaging analysis software 
(ImageJ) by measuring the signal intensity of several areas of each tumor, excluding the 
necrotic core. The measurements from each mouse were normalized by the signal intensity 
of nearby muscle tissue.
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RESULTS
Mn-corrole has the greatest effect on T1 relaxation rate and MRI contrast enhancement 
compared to Feand Ga- corroles
We screened several metallated corroles for their ability to augment T1 relaxation rates and 
MRI contrast in solution in order to select the best candidate for subsequent evaluation in 
vivo. Based on their paramagnetic potential, sulfonated manganese, iron, and gallium -
metallated corroles (S2Mn, S2Fe, and S2Ga, respectively) were chosen for such 
comparisons (chemical structure shown in Fig. 1A). The T1 relaxation time shortening 
induced by each compound remained unchanged whether the solvent was water, phosphate 
buffered saline (PBS), or Hanks Balance Salt Solution (HBSS) (Fig. 1B). Of the three 
compounds measured, S2Mn, exhibited the largest T1 time shortening (Fig. 1B) and contrast 
enhancement (Fig. 1C) in vitro, and was selected for evaluation in vivo.
To determine the threshold of detecting S2Mn in tissue, we delivered known dosages of 
S2Mn at escalating concentrations directly into tumors on mice and monitored T1 relaxation 
shortening and corresponding contrast enhancement. Specifically, a mouse bearing 
subcutaneous bilateral flank tumors received intratumoral (IT) injections of either S2Mn at 
escalating doses or saline (in the contralateral tumor) followed by measurement of T1 time 
shortening and MR image acquisition, captured after each dose escalation. An IT 
accumulation of ≤3 nmoles S2Mn yielded no significant relaxation time reduction (Fig. 1D), 
and likewise produced no MRI contrast-enhancing signal (Fig. 1E). However, injection of 
33 nmoles of S2Mn in the tumor yielded a significant difference in T1 time shortening 
compared to the equivalent volume of saline injected into the contralateral tumor (Fig. 1D) 
(p<0.05), and could be measured in the same tumor up to two weeks after injection (Fig. 1D) 
(p<0.05). Likewise, this dose produced a detectable MR contrast enhancement over saline at 
the injection site (Fig. 1E). Based on the approximate area of contrast detected in the tumor, 
a minimum threshold between 3–33 nmoles of Mn-corrole per ~100 mm3 area of tissue is 
sufficient to yield tumor-to-tissue contrast enhancement, and provides a basis for 
determining the minimum in situ dosage required to yield a contrast signal.
HerMn assembly reduces corrole influence on T1 relaxation rate
We combined S2Mn with HerPBK10 in order to assemble complexes to test for targeting 
tumors after systemic delivery. Particle characterization included verifying the formation of 
protein-corrole assemblies and more importantly, assessing the effect of protein-corrole 
binding on T1 relaxation. To form particles, we combined S2Mn with HerPBK10 and 
filtered the resulting mixture to remove free corrole. The binding occurring between S2Mn 
and HerPBK10 was evidenced by corrole absorbance that remained in the retentate after 
filtration (Fig. 2A; “HerMn retentate”). The absorption spectrum of HerMn corresponded 
with that of free S2Mn that did not undergo ultrafiltration (Fig. 2A; “S2Mn unfiltered”), and 
contrasted with that of free corrole alone, which passed through the filter, and thus was not 
detected in the retentate (Fig. 2A; “S2Mn retentate”). The HerMn particles recovered from 
ultrafiltration retentates yielded an average diameter of 23.2 ± 1.81 nm, as detected by 
dynamic light scattering (Fig. 2B–C). These findings were confirmed by electron 
microscopy imaging and analysis, which showed that HerMn formed sphere-like particles 
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that were approximately 20 nm in diameter (Fig. 2D). HerMn particles typically formed at a 
corrole:protein ratio of 30 ± 6 corrole molecules per HerPBK10 monomer (Table S1).
HerMn-enhanced T1 shortening and MRI contrast is activated by cell internalization
A comparison of HerMn and S2Mn in solution shows that particle formation considerably 
reduces the effect of the corrole on T1 relaxation rate (Fig. 3A). However, direct delivery of 
HerMn into tissue yields substantial tumor-to-tissue contrast enhancement (Fig. 3B) and 
significant T1 relaxation shortening (Fig. 3C) at the injection site. Taken together, these 
findings suggest that corroles are limited from interaction with water molecules in the intact 
HerMn particle but become solvent exposed upon tissue entry. To see if the low pH 
microenvironment of the tumor or endosomes facilitates corrole release and subsequent 
contrast enhancement, we incubated HerMn at pH 5.5 (mimicking the acid environment of 
late endosomes/lysosomes)(21). These conditions did not significantly impact T1 relaxation 
rate of either S2Mn or HerMn solutions, in comparison to incubation at neutral pH (7.4) 
(Fig. 3A). Therefore, we examined the contribution of cell uptake on T1 relaxation.
S2Mn and HerMn were incubated on MDA-MB-435 cells in suspension under conditions 
promoting binding and internalization, and T1 relaxation rates were measured before and 
after uptake. Importantly, non-internalized particles were removed from cell surfaces before 
measuring relaxation time, and cells were quantified for internalized corroles afterward. 
After cell uptake, HerMn yielded a 31% T1 relaxation rate increase, whereas S2Mn alone 
mediated a 23% lower T1 relaxation rate (Fig. 3D). Together these findings indicate that 
cellular internalization but not acidic conditions trigger HerMn-enhanced T1 shortening.
HerMn-mediated tumor homing enables tumor-selective MRI in vivo
Before assessing the capacity of HerMn for in vivo MRI after systemic delivery, we first 
used optical imaging to evaluate its biodistribution. Mice bearing subcutaneous left flank 
MDA-MB-435 tumors received a single tail vein injection of fluorescently-labeled HerMn 
followed by optical image capture at sequential time points after delivery. Whole animal 
imaging shows that HerMn fluorescence accumulates in tumors immediately after 
intravenous (IV) delivery, and is retained in tumors up to 24 hours later while circulating 
fluorescence is cleared from elsewhere in the body (Fig. 4A). Fluorescence images of 
tumors and organs harvested from sacrificed mice were compared to those from mice 
receiving Mn-corrole combined with labeled bovine serum albumin (BSA) to form a non-
targeted control particle (BSA-Mn). HerMn exhibited preferential accumulation to the tumor 
with low (liver, kidney) to undetectable (heart, lung, spleen, skeletal muscle) distribution to 
non-tumor tissue (Fig. 4B–C). In contrast, BSA-Mn exhibited higher lung, kidney and 
spleen distribution and lower tumor accumulation compared to HerMn, while liver 
distribution was relatively similar (Fig. 4B–C).
The tumor-preferential biodistribution of HerMn suggests that the particle can facilitate 
sufficient tumor accumulation to enhance tumor-to-tissue contrast after systemic delivery. 
To test this, HER2+-tumor bearing mice received daily IV injections of HerMn (8 nmoles 
per injection for 8 days) followed by MRI after the final injection. HerMn significantly 
enhanced contrast in tumors compared to non-tumor tissue (approximal muscle tissue) and 
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in comparison to S2Mn, HerPBK10, and saline-treated groups (Fig. 4D–E). Additionally, 
mice treated with clinically-used doses of gadolinium produced similar levels of contrast 
enhancement as HerMn (Fig. 4D–E). However, it is important to note that whereas the Gd-
treated mice were imaged immediately after Gd injection, the HerMn-treated mice (and 
additional controls) were imaged 24h after the final injection. The prolonged retention of the 
particle in tumors could be advantageous over Gd, which is known to clear quickly after 
injection(22) and is consistent with our previous studies showing that HerPBK10-mediated 
delivery of a gallium-metallated corrole enabled tumorretention of the molecule up to 30 
days after injection.(23)
Systemic delivery of HerMn is accompanied by tumor-toxicity
The systemic accumulation of HerMn in tumors led us to examine its effect on tumor growth 
and survival, especially in light of previous studies showing that the Mn-corrole can be 
cytoprotective. (6, 24) Therefore, tumor-bearing mice receiving systemic HerMn (5 nmoles 
or 0.00022 mg/kg per day for 6 days) were monitored for tumor growth rates in comparison 
to control mice injected with either S2Mn, HerPBK10, or saline (average tumor size: 200 
mm3 at initiation of injections) (Fig. 5A). HerMn treatment resulted in a marked reduction in 
tumor volume, while HerPBK10 and S2Mn alone had no effect on tumor growth, similar to 
the mock (saline)–treated mice (Fig. 5B–C).
We also examined this on several tumor cell lines in culture by measuring overall viability 
of HER2+ (MDA-MB-435, SKBR3, and BT-474) and HER2− (MDA-MB-231) cells when 
exposed to escalating concentrations of either HerMn or the untargeted corrole, S2Mn. 
HerMn treatment resulted in concentration-dependent cell death in the HER2+ but not 
HER2− cells whereas the corrole alone (lacking a delivery agent) at equivalent 
concentrations did not affect viability (Fig. 5D). HerPBK10 alone is already known to have 
no effect on the viability of these cell lines. (3, 10, 11, 15) Importantly, we found that at 
equivalent concentrations, HerMn elicits significantly greater cell death compared to 
clinically approved anti-HER2 therapies, trastuzumab, and trastuzumab/pertuzumab in 
combination (Fig. 5E).
As an assessment of clinical translatability and safety, we examined whether HerMn affects 
the viability of primary human cardiosphere-derived cells (CDCs). Unlike mouse 
myocardium, human myocardium is adversely impacted by HER2-targeted therapies 
currently used in the clinic, which exacerbate the cardiotoxicity of anthracycline-based 
therapies.(25) Cardiospheres are derived from endomyocardial biopsies obtained from 
healthy hearts of deceased tissue donors, and are comprised mainly of cardiomyocytes, 
endothelial cells, and smooth muscle cells,(26) thus providing a reasonable representation of 
human cardiac tissue for in vitro studies. These cells express HER subunits at similar levels 
as human heart tissue.(27) Here, escalating concentrations of HerMn and individual 
components (HerPBK10 alone and S2Mn alone) had no detectable effect on CDC viability 
in contrast to doxorubicin (Dox) (Fig. 5F), which is known to cause acute myocardial 
cytotoxicity.(28) Microscopy shows cell rounding and lifting of Dox treated cells whereas 
HerMn caused no such morphological changes (Fig. 5G).
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Targeted toxicity by HerMn is mediated by mitochondrial membrane disruption and 
oxidative damage to the cytoskeleton
The observed tumor-toxicity of HerMn was somewhat unexpected, as the Mn-corrole has 
exhibited cytoprotective effects on neuronal cells in previous studies (6, 24, 29). Hence, we 
investigated the possible mechanisms contributing to HerMn-mediated tumor toxicity. 
Porphyrin-like compounds can be cytotoxic through mitochondrial and cytoskeletal 
disruption, leading to apoptotic cell death.(30) In agreement, we have seen that a gallium-
metallated corrole induces intracellular superoxide elevation, resulting in oxidative damage 
to the mitochondrial membrane and cytoskeleton.(10) To determine whether HerMn-
mediated cytotoxicity is consistent with this, we examined the impact of HerMn on 
mitochondrial membrane potential by measuring its effect on uptake of the cationic dye, 
tetramethyl rhodamine methyl ester (TMRM). Mock (HBSS)–treated cells exhibited intense 
fluorescence indicative of dye accumulation in mitochondria, whereas 10 µM S2Mn alone 
slightly reduced this fluorescence intensity (Fig. 6A–B). In contrast, HerMn at equivalent 
and lower concentrations substantially reduced fluorescence intensity (Fig. 6A–B), and 
elicited a concentration-dependent loss of mitochondrial membrane potential (Fig. 6A). 
Importantly, the conditions of treatment allowed for the monitoring of mitochondrial 
function before cells became necrotic, as indicated by the retention of cell attachment to the 
substratum (Fig. 6B). An examination of cytoskeletal integrity showed that HerMn, but not 
HerPBK10 or S2Mn alone, caused breakdown of actin and microtubules, resulting in 
cytoplasmic collapse (Fig. 6C). Treating the cells with the oxygen scavenger, Tiron, before 
adding HerMn, preserved the cytoskeletal structure (Fig. 6C), suggesting that reactive 
oxygen species contribute to HerMn-mediated cytoskeletal disruption.
DISCUSSION AND CONCLUSIONS
These studies demonstrate that a sulfonated manganese(III) corrole can be used as an MRI 
contrast-enhancing agent and induce cytotoxicity while retaining the high protein binding 
capability of corrole molecules. This latter feature has enabled the non-covalent assembly of 
HerMn, in which the tumor-targeting and penetration features of HerPBK10 are combined 
with the dual cytotoxic and paramagnetic properties of a manganese(III) corrole. The 
advantages of this particle over conventional contrast agents include its ability to target 
tumors, and impart both imaging and therapeutic activities. Importantly, these studies show 
that HerMn has improved toxicity to HER2+ tumor cells over the HER2-targeted signal-
inhibitors, trastuzumab and pertuzumab, which are currently used in the clinic. Taken 
altogether, these findings suggest that HerMn may have potential clinical impact.
Selective targeting of HerMn to HER2+ but not HER2− tumor cells in vitro and 
significantly higher tumor-accumulation compared to a non-specific protein (BSA) bound to 
Mn-Corrole in vivo together indicate that active targeting, in contrast to enhanced 
permeability and retention (EPR), is a major contributor to the tumor homing observed here. 
These findings support our previous studies showing that HerPBK10 exhibits preferential 
targeting in vivo to tumors displaying relatively higher HER2–3 levels in contrast to those 
expressing low/negligible levels of HER2–3 (15). Unlike gadolinium, which is known to 
clear quickly after injection (22), our data indicates that HerMn is retained to allow 
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sufficient imaging even 24h after injection. Thus it is possible to allow tumor accumulation 
over time to enable both imaging during or after treatments, and therapeutic efficacy.
The non-distribution and non-toxicity to heart tissue, especially in human cardiac tissue, 
presents a major advantage over traditional chemotherapy reagents such as anthracyclines, 
which have known cardiotoxic effects.(28) Previous studies show that the Mn-corrole is 
neuroprotective at low (≤1 µM) levels but toxic at higher concentrations,(6) hence high local 
accumulation in tumors afforded by targeted delivery likely contributes to tumor toxicity 
while sparing heart tissue. Notably, HerMn appeared to transiently localize to the head 
region (15–30 min), which could result from either extra-cranial circulation or specific 
delivery to the brain. We are exploring the latter in separate studies, given that HER3 
expression on brain endothelium mediates neuregulin transcytosis into brain parenchyma.
(31) If confirmed, such findings could have important implications with regard to targeting 
metastatic tumors.
Our mechanistic studies on the gallium-metallated corrole nanoparticle, HerGa (comprising 
HerPBK10 and a sulfonated gallium-metallated corrole) show that endosomal escape is 
required for corrole-mediated cytotoxicity after cell entry (10). Additionally, those studies 
show that the Ga-corrole induces superoxide elevation, causing oxidative damage to the 
mitochondrial membrane and cytoskeleton (10). The mitochondrial membrane disruption 
and superoxide-mediated cytoskeletal collapse observed here suggest that HerMn acts 
through similar mechanisms, and is likely to also require cytoplasmic entry for accessing 
molecular targets of toxicity. One such target may be the translocator protein, TSPO, which 
mediates porphyrin passage into mitochondria and contributes to cellular homeostasis (32, 
33). We have recently found that this molecule is a target of the gallium-metallated 
compound (manuscript in preparation). The elevation of this protein in cancer cells (34, 35) 
may sensitize tumors to this and other metallated corroles, thus adding to tumor-selective 
toxicity.
The slower relaxation mediated by HerMn compared to S2Mn in solution suggests that 
corrole binding to HerPBK10 may constrain the interaction of manganese(III) centers with 
water molecules in the saline suspension. However, this does not seem to interfere with its 
contrast-enhancing capability in vivo, specifically in tissue, suggesting that the corroles in 
HerMn become solvent-exposed upon cell uptake. Such a feature would enable tumor-
selective imaging and detection by combining targeting with internalization-triggered 
contrast enhancement. Our in vitro findings on cells in culture are consistent with this 
prediction and furthermore indicate that postendocytic processes rather than acidic 
conditions of the endosome contribute to this. The latter feature is advantageous by avoiding 
the need for the particle to localize in late endosomes/lysosomes to release the corrole, 
which would otherwise mitigate its therapeutic effect. This additionally avoids premature 
release of the contrast agent under acidic environments outside of the tumor or conversely 
retention of the contrast agent if the particle remains in a neutral intracellular compartment, 
which would both confound imaging analysis and interpretation. Taken together with the 
earlier systemic delivery results, these studies show that HerMn enables tumor-selective 
detection through both targeting and activatable T1-relaxation shortening triggered by cell 
uptake.
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Collectively, the multifunctional features of each component comprising HerMn contribute 
to its translational potential as a tumor-targeted therapeutic agent with clinically-relevant 
imaging capabilities as well as activatable, tumor-selective detection.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Effect of Ga-, Fe-, and Mn- corroles on T1 relaxation rate and contrast change
A, Chemical structure of a metallated sulfonated corrole. S2Mn, S2Fe, and S2Ga are 
specified by replacement of metal ion (M) with Mn(III), Fe(III) or Ga(III), respectively. B–
C, T1 relaxation times and contrast image of S2Mn, S2Fe, and S2Ga solutions in vitro. 
Graphs in B show T1 relaxation time measurements of indicated buffer solutions in 
Eppendorf tubes containing increasing concentrations of each corrole. N=3 per 
concentration. Image in C shows the contrast change acquired from PBS containing 
indicated concentrations of corroles measured in B. D–E, T1 relaxation measurements and 
MRI of IT-injected tumors. Mice bearing HER2+ bilateral flank MDA-MB-435 tumors 
received IT injections of S2Mn in right tumors and equivalent volumes of saline in left 
tumors followed by (D) measurement of T1 change, and (E) MR image acquisition after 
delivery of indicated doses of S2Mn. In D, contralateral (left) tumors injected with saline are 
indicated by open bars. *, p<0.05 as determined by t-test comparing S2Mn and saline. N=8 
different recovery intervals.
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Figure 2. Characterization of HerMn particle
A, Binding and retention of S2Mn to HerPBK10. S2Mn incubated −/+ HerPBK10 was 
subject to ultrafiltration. Retentates were recovered and analyzed by UV/Vis 
spectrophotometry. Absorbance curves show spectra of: “unfiltered S2Mn” (top panel); 
retentate of S2Mn incubated with HerPBK10 after filtration (“HerMn retentate”; middle 
panel); and, retentate of S2Mn alone after filtration (“S2Mn retentate”; bottom panel). B–C, 
Particle sizing of S2Mn, HerPBK10, and HerMn. Histograms in B show diameter (nm) and 
population distribution of S2Mn, HerPBK10, and HerMn particles in solution using dynamic 
light scattering (Zetasizer Nano, Malvern). Average diameters (nm) of corresponding 
particle populations are summarized in C. D, Electron microscopy of particles. Arrows 
highlight representative particles. Right panels show enlargements of boxed regions, and are 
contrast-enhanced to distinguish particle from background.
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Figure 3. Effect of tissue, pH, and cell uptake on HerMn-mediated T1 time and contrast change
A, Comparison of HerMn and S2Mn, and effect of pH on T1 relaxation in vitro. Increasing 
concentrations of S2Mn or HerMn were incubated in PBS, pH 7.4 or 5.5, for 30 min before 
T1 relaxation rates were measured by MR. N=3 per concentration. B–C, MRI and T1 
relaxation measurements of IT-injected tumors. Mice bearing HER2+ bilateral flank MDA-
MB-435 tumors received daily IT injections of HerMn (50 nmoles/injection)(+) in the right 
flank tumor or saline(−) in the left flank tumor for 8 days. In (B), “Left” and “Right” refer to 
left and right flank tumors on the same mice. Tumor-to-tissue contrast (B) and 
corresponding T1 relaxation rates (C) were acquired after the final injection. IT injected 
tumors receiving 33.33 nmoles S2Mn and corresponding T1 time change (from Fig. 1D–E) 
are shown as a comparison. N=8 different recovery intervals. D, Effect of cell uptake on T1 
relaxation rate. T1 relaxation rates were obtained from S2Mn or HerMn samples in PBS 
alone or after uptake in MDA-MB-435 cells, representing Pre- and Post- cell uptake 
conditions, respectively. T1 relaxation rate changes were normalized by the concentration of 
corrole present in each condition (input corrole concentration for pre-cell uptake, and corrole 
concentration recovered from cell lysates for post-cell uptake). *, p< 0.05 in C–D as 
determined by 2-tailed t-test.
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Figure 4. Biodistribution and MRI after systemic delivery of HerMn
A–C, Biodistribution of HerMn. HER2+ tumor-bearing mice receiving an IV injection of 
fluorescently-labeled HerMn or BSAMn were (A) imaged live at the indicated time points. 
Tumors are indicated by arrows. B–C shows tissue distribution of HerMn from mice in A 
after the 24h time point. Panels beneath bar graph show representative tissues (each from the 
same respective mouse) and fluorescences measured by the Xenogen imager. N≥6 
measurements per tissue. D, MRI after systemic delivery in vivo. Images (left panels) show 
cross-sections of tumor-bearing mice before and after receiving IV injections of HerMn, 
S2Mn, gadolinium (Gd; Optimark™ gadoversetamide), or saline. Tumors are delineated by 
boxed regions, which are enlarged in middle panels and rendered in black and white (B/W) 
mode (50% black and white pseudo-coloring) to highlight regions of contrast (right panels). 
E, MRI contrast comparisons between treatment groups in vivo. *, p<0.05 as determined by 
t-test comparing HerMn and saline or HerMn and S2Mn. Saline, HerMn, S2Mn treatments: 
N=5 measurements per tumor, per mouse (5 mice/group); Gd injected mice: N=3 
measurements per tumor per mouse (3 mice/group).
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Figure 5. Therapeutic efficacy of HerMn
A–C, Tumor growth after systemic delivery of HerMn. Regimen of tumor growth and 
treatment is shown in A. Tumor volumes (growth curves shown in B) were measured before 
(day 1), during (day 3), and after (days 8, 15, and 22) tail vein injections of indicated 
reagents. N=8–10 tumors per group. *, p<0.05 comparing HerMn vs each control group at 
day 15, and HerMn vs S2Mn at day 22 (several control animals required sacrifice from 
tumor burden, resulting in loss of power between the other two control groups and HerMn at 
day 22). Mouse image (C) shows comparison of tumor sizes of representative mice treated 
with saline or HerMn. D, Effect of HerMn on human HER2+ and HER2− tumor cell 
survival. Each cell line received the indicated concentrations of either HerMn or S2Mn and 
was subsequently assessed for cell survival 24h later via crystal violet (CV) stain. N=3 per 
concentration, from three separate experiments. E, Comparison to HER2-targeted therapies 
used in the clinic. MDA-MB-435 cells received the indicated concentrations of HerMn, 
trastuzumab (Tz) or trastuzuamb-pertuzumab combination (Tz + Pz) and were subsequently 
assessed for cell survival 48 hours later via metabolic (MTS) assay. N=3 per concentration, 
from 3 separate experiments. F–G, Human CDC viability after HerMn treatment. Human 
cardiosphere-derived cells (CDCs) received the indicated concentrations of either HerMn, 
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S2Mn, HerPBK10, or doxorubicin (Dox) and were subsequently assessed for cell survival 
48 hours later via MTS assay. N=3 per concentration, from three separate experiments. 
Images in G show unfixed CDCs under brightfield light after 2 days of incubation in 5 µM 
Dox or HerMn.
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Figure 6. Mechanism of HerMn cytotoxicity
A–B, Effect of HerMn on mitochondrial membrane potential (ΔΨm). MDA-MB-435 cells 
were treated with 10 µM S2Mn or HerMn at the indicated concentrations, and assessed for 
mitochondrial membrane integrity 24 h later by measurement of TMRM uptake. A, 
Measured quantum yield of TMRM fluorescence per cell from at ≥3 independent fields per 
experiment. Measurements are shown as the fluorescence intensity (FI) of experimental 
groups normalized by control (PBS) treatment. N=3 experiments. *, p<0.01 compared to 
control. B, Micrographs showing z-stacked maximum intensity projections of TMRM red 
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fluorescence in cells treated with the indicated concentrations of reagents. Scale bar=~10 
microns. C, Effect of HerMn on the cytoskeleton. Micrographs show fluorescence labeling 
of actin (red) and tubulin (green) in HER2+ MDA-MB-435 cells after treatment for 24 h 
with HerMn or S2Mn (each at 5 µM corrole concentration), HerPBK10 (at equivalent 
protein concentration as HerMn) or PBS (control). Where indicated, cells received Tiron (5 
mM) for one hour before HerMn treatment. Blue, nucleus. Scale bar=~10 microns. Lower 
and higher magnification images are shown in Fig. S1.
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